Tango Therapeutics (TNGX) Following Trial Update Has Its Valuation Story Back In Focus

Tango Therapeutics (TNGX) has drawn fresh attention after reporting updated Phase 1/2 data for vopimetostat combined with RAS(ON) inhibitors in MTAP-deleted, RAS-mutant pancreatic and lung cancers, alongside plans for a global registrational trial. The share price reaction has been choppy around the news. Tango Therapeutics is up 3.13% on a 1-day share price return to US$22.89 but down 9.35% over 7 days and 8.15% over 30 days, while the year-to-date share price return of 156.33% and 1-year...